- Home
- ALTS vs CTNM Comparison
ALTS vs CTNM Comparison
Compare ALTS & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTS
- CTNM
- Stock Information
- Founded
- ALTS 1976
- CTNM 2009
- Country
- ALTS United States
- CTNM United States
- Employees
- ALTS N/A
- CTNM N/A
- Industry
- ALTS
- CTNM
- Sector
- ALTS
- CTNM
- Exchange
- ALTS NYSE
- CTNM Nasdaq
- Market Cap
- ALTS 109.1M
- CTNM 114.1M
- IPO Year
- ALTS N/A
- CTNM 2024
- Fundamental
- Price
- ALTS $9.31
- CTNM $3.66
- Analyst Decision
- ALTS
- CTNM Strong Buy
- Analyst Count
- ALTS 0
- CTNM 4
- Target Price
- ALTS N/A
- CTNM $22.50
- AVG Volume (30 Days)
- ALTS 251.8K
- CTNM 102.0K
- Earning Date
- ALTS 05-13-2025
- CTNM 05-14-2025
- Dividend Yield
- ALTS N/A
- CTNM N/A
- EPS Growth
- ALTS N/A
- CTNM N/A
- EPS
- ALTS N/A
- CTNM N/A
- Revenue
- ALTS $18,046,000.00
- CTNM N/A
- Revenue This Year
- ALTS N/A
- CTNM N/A
- Revenue Next Year
- ALTS N/A
- CTNM N/A
- P/E Ratio
- ALTS N/A
- CTNM N/A
- Revenue Growth
- ALTS N/A
- CTNM N/A
- 52 Week Low
- ALTS $1.29
- CTNM $3.35
- 52 Week High
- ALTS $10.40
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- ALTS 81.41
- CTNM N/A
- Support Level
- ALTS $6.34
- CTNM N/A
- Resistance Level
- ALTS $9.84
- CTNM N/A
- Average True Range (ATR)
- ALTS 0.89
- CTNM 0.00
- MACD
- ALTS 0.30
- CTNM 0.00
- Stochastic Oscillator
- ALTS 95.23
- CTNM 0.00
About ALTS ALT5 SIGMA CORPORATION
ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.